FDA OCE commentary: Cancer burden facing Asian Americans partly caused by racism

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A commentary authored by seven researchers who participated in the FDA Oncology Center of Excellence “Conversations on Cancer,” held July 29, 2021, discussed the significant cancer disparities facing Asian Americans. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

A multidisciplinary team of experts in lung cancer screening and implementation science from the UCLA Health Jonsson Comprehensive Cancer Center, the David Geffen School of Medicine at UCLA, and the UCLA Fielding School of Public Health, was awarded a $2.5 million grant from the Bristol Myers Squibb Foundation, an independent charitable organization, to spearhead a new initiative aimed at reducing disparities in lung cancer screening across Los Angeles County. 
After reading “Breast Cancer Mortality Continues Three-Decade Decline, but Steeper Increases for Women Under 50 & AAPI Women of All Ages,” it is evident that while overall progress is being made in the fight against cancer, concerning disparities remain—particularly within the Native Hawaiian and Pacific Islander (NHPI) communities. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login